Best practice in precision medicine for prostate cancer
Best practice in precision medicine for prostate cancer
Visugromab plus nivolumab significantly increases pathologic response in muscle-invasive bladder cancer
ESMO 2025: Bladder cancer highlights
ESMO 2025: Prostate highlights
ESMO 2025: Renal highlights
Sacituzumab tirumotecan improves progression-free and overall survival in EGFR-TKI resistant NSCLC
Sacituzumab govitecan improves PFS in first-line metastatic TNBC patients unable to receive PD-(L)1 inhibitors
177Lu-PSMA-617 in metastatic castration-resistant prostate cancer shows higher PSA response with lower toxicity
Perioperative enfortumab vedotin plus pembro improves survival and pCR in cisplatin-ineligible MIBC
Avelumab maintenance after reduced chemotherapy cycles improves QoL without sacrificing survival in aUC
Trastuzumab deruxtecan improves disease-free survival vs trastuzumab emtansine in high-risk HER2+ early breast cancer
Non-clear cell renal cell carcinoma: Management of papillary RCC